Statins and the acute-phase response

New England Journal of Medicine

Volumn 344, Issue 26, 2001, Pages 2016-2018

  Munford, R S ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; STATIN;

ACUTE PHASE RESPONSE; ATHEROSCLEROSIS; BLOOD CLOTTING; DIAGNOSTIC VALUE; EDITORIAL; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL;

ACUTE-PHASE REACTION; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN;

EID: 0035963505     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200106283442609     Document Type: Editorial

References (15)

1. IL-6 and APPs: Anti-inflammatory and immunosuppressive mediators
2. Normal responses to injury prevent systemic inflammation and can be immunosuppressive
3. Infection and inflammation-induced proatherogenic changes of lipoproteins
4. Insulin resistance and inflammation in an evolutionary perspective: The contribution of cytokine genotype/phenotype to thriftiness
5. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
6. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
7. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability
8. C-reactive protein (CRP) elevation can be caused by conditions other than inflammation and may reflect biologic aging
9. Fibrinogen and coronary risk
10. Simvastatin has antiinflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering
11. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels
12. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
13. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
14. HMG-CoA reductase inhibitors and the risk of fractures
15. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors